stockrow
Friday 6 November 2026
Export NDRA’s income statement to Excel — free account
ENDRA Life Sciences Inc.
NDRA Healthcare Diagnostics & Research
- EPS
- +107.0%
- Free cash flow
- +15.0%
Quarter to June 2026, against a year earlier
4.70
0.31
−6.19%
Follow NDRA
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 5 | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
P/S ratio |
0.00 | 19.97 | 14.67 | — | — | — | — | — | — | — |
Altman Z-Score |
— | 3.94 | (4.33) | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(124.25) | (2.68) | (8.73) | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
P/Operating CF |
(11.95) | (12.60) | (2.76) | — | — | — | — | — | — | — |
P/B ratio |
1.75 | 3.28 | 0.84 | — | — | — | — | — | — | — |
Price to Tangible BV |
1.75 | 3.28 | 0.84 | — | — | — | — | — | — | — |
EV/Sales |
0.00 | 13.51 | (3.41) | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.15 | — | — | — | — | — | — | — |
EV/Operating CF |
(3.19) | (3.55) | 0.16 | — | — | — | — | — | — | — |
EV/FCF |
(3.19) | (3.54) | 0.16 | — | — | — | — | — | — | — |
Quick Ratio |
0.10 | 6.61 | 6.64 | 2.98 | 7.32 | 6.13 | 2.87 | 3.14 | 5.34 | 1.02 |
Current Ratio |
0.14 | 6.93 | 7.13 | 3.15 | 8.32 | 7.83 | 4.71 | 3.36 | 5.67 | 1.29 |
Net Debt/EBITDA |
(0.97) | 1.45 | 0.79 | 0.67 | 0.61 | 0.83 | 0.38 | 0.27 | 0.30 | 0.14 |
Debt/Assets |
193.56% | 0.00% | 0.00% | 9.85% | 4.72% | 1.25% | 0.31% | 0.42% | 0.00% | 0.00% |
Debt/Equity |
(1.06) | 0.00 | 0.00 | 0.15 | 0.06 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
Asset Turnover |
0.16 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.47 | 0.61 | 0.79 | 0.49 | 0.89 | 0.98 | 0.97 | 0.95 | 0.64 | 0.74 |
Capex/Depreciation |
0.00 | (0.01) | (0.13) | (0.02) | (0.19) | (0.20) | (0.86) | (0.09) | (0.06) | (19.18) |
| (126.68%) | (245.43%) | (170.02%) | (318.39%) | (203.20%) | (126.46%) | (146.53%) | (156.42%) | (280.02%) | (291.56%) | |
| (83.92%) | (162.58%) | (146.80%) | (243.43%) | (152.07%) | (104.92%) | (119.01%) | (125.53%) | (205.38%) | (169.21%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (2,021.57%) | (484.39%) | (350.85%) | (230.43%) | 0.00% | (240.50%) |
Return on Tangible Assets |
310.55% | (101.92%) | (156.79%) | (373.00%) | (163.07%) | (106.28%) | (201.02%) | (448.82%) | (397.13%) | (2,708.05%) |
Average Days of Receivables |
0.00 | 7.16 | 0.00 | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
96.08% | 549.23% | 76,169.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
305.68% | 817.35% | 64,761.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.55 | 0.29 | 1.14 | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Earnings Yield |
(100.55%) | (50.45%) | (144.51%) | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(14.06%) | (19.10%) | (148.61%) | — | — | — | — | — | — | — |
Revenue per Share |
0.00 | 4,463.62 | 48.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.00 | (41,905.44) | (59,843.51) | (42,944.50) | (21,493.20) | (9,268.67) | (7,511.41) | (2,652.44) | (36.64) | (6.59) |
Capex per Share |
0.00 | (100.29) | (776.94) | (218.00) | (150.60) | (37.50) | (119.18) | (6.86) | (0.06) | (3.83) |
Free Cash Flow per Share |
0.00 | (42,005.73) | (60,620.45) | (43,162.50) | (21,643.80) | (9,306.17) | (7,630.59) | (2,659.31) | (36.70) | (10.42) |
Cash per Share |
0.00 | 71,117.00 | 50,278.65 | 30,871.00 | 14,454.60 | 7,884.58 | 2,875.94 | 787.19 | 15.99 | 0.97 |
Shareholders Equity per Share |
0.00 | 66,973.30 | 48,544.53 | 23,803.50 | 14,338.60 | 8,986.92 | 4,237.94 | 1,571.94 | 12.68 | 2.87 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 66,973.30 | 48,544.53 | 23,803.50 | 14,338.60 | 8,986.92 | 4,237.94 | 1,571.94 | 12.68 | 2.87 |
Free Cash Flow |
(1.32) | (3.31) | (7.80) | (8.63) | (10.82) | (11.17) | (12.97) | (9.57) | (7.41) | (8.20) |
Working Capital |
(1.19) | 5.03 | 5.98 | 4.46 | 7.22 | 10.55 | 6.32 | 2.13 | 2.83 | 0.22 |
Capital Expenditures |
— | (0.01) | (0.10) | (0.04) | (0.08) | (0.04) | (0.20) | (0.02) | (0.01) | (3.02) |
Net Current Asset Value |
(1.19) | 5.03 | 5.98 | 4.12 | 6.61 | 10.00 | 5.95 | 1.94 | 1.54 | (0.63) |
EV/EBIT |
0.00 | 0.00 | 0.14 | — | — | — | — | — | — | — |
Capex to Sales |
0.00 | 0.02 | 16.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.27 | 3.20 | 2.92 | 11.51 | 1.87 | 1.71 | 0.99 | 2.46 | 2.98 | 3.70 |
Cash ROIC |
(653.88%) | (30.42%) | (61.34%) | (74.15%) | (73.07%) | (54.72%) | (107.01%) | (112.35%) | (128.04%) | (271.30%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.39 | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
2.04 | 1.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
672.44 | 1,791.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
62.05 | 404.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Payables |
0.61 | 0.64 | 0.91 | 1.34 | 1.31 | 1.16 | 1.47 | 1.11 | 0.60 | 0.56 |
Average Inventory |
0.12 | 0.12 | 0.13 | 0.09 | 0.35 | 0.94 | 1.96 | 2.63 | — | — |
Average Assets |
3.31 | 3.31 | 6.67 | 7.20 | 7.97 | 10.82 | 11.07 | 8.01 | 5.60 | 4.15 |
Average Common Equity |
2.19 | 2.19 | 5.76 | 5.50 | 5.97 | 8.98 | 8.99 | 6.43 | 4.11 | 2.41 |
Columns are period end dates · fundamentals updated 26 Oct 2026